Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of MT-7117 in Hepatic Impairment
NCT04116476Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration time curve from time zero to last quantifiable concentration and 1 more. Started Aug 2019; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT04116476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116476.